ZYME Zymeworks Inc

Price (delayed)

$9.12

Market cap

$644.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.78

Enterprise value

$555.15M

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of ...

Highlights
The company's debt fell by 8% YoY and by 6% QoQ
The quick ratio has increased by 9% year-on-year but it has declined by 6% since the previous quarter
Zymeworks's net income has shrunk by 173% YoY and by 6% QoQ
ZYME's EPS has dropped by 165% year-on-year and by 3.5% since the previous quarter

Key stats

What are the main financial stats of ZYME
Market
Shares outstanding
70.7M
Market cap
$644.83M
Enterprise value
$555.15M
Valuations
Price to book (P/B)
1.47
Price to sales (P/S)
13.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11
Earnings
Revenue
$50.46M
EBIT
-$127.86M
EBITDA
-$111.14M
Free cash flow
-$75.05M
Per share
EPS
-$1.78
Free cash flow per share
-$0.98
Book value per share
$6.21
Revenue per share
$0.66
TBVPS
$7.01
Balance sheet
Total assets
$553.75M
Total liabilities
$115.75M
Debt
$25.13M
Equity
$438M
Working capital
$336.93M
Liquidity
Debt to equity
0.06
Current ratio
6.92
Quick ratio
6.61
Net debt/EBITDA
0.81
Margins
EBITDA margin
-220.2%
Gross margin
100%
Net margin
-249.6%
Operating margin
-294.4%
Efficiency
Return on assets
-22%
Return on equity
-28.4%
Return on invested capital
-33.4%
Return on capital employed
-25.7%
Return on sales
-253.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZYME stock price

How has the Zymeworks stock price performed over time
Intraday
-2.77%
1 week
3.52%
1 month
3.05%
1 year
-0.76%
YTD
-12.22%
QTD
-13.31%

Financial performance

How have Zymeworks's revenue and profit performed over time
Revenue
$50.46M
Gross profit
$50.46M
Operating income
-$148.57M
Net income
-$125.97M
Gross margin
100%
Net margin
-249.6%
ZYME's operating income has dropped by 184% year-on-year and by 8% since the previous quarter
Zymeworks's net income has shrunk by 173% YoY and by 6% QoQ
Zymeworks's revenue has plunged by 89% YoY and by 34% from the previous quarter
Zymeworks's gross profit has shrunk by 89% YoY and by 34% QoQ

Growth

What is Zymeworks's growth rate over time

Valuation

What is Zymeworks stock price valuation
P/E
N/A
P/B
1.47
P/S
13.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11
ZYME's EPS has dropped by 165% year-on-year and by 3.5% since the previous quarter
ZYME's P/B is 49% below its 5-year quarterly average of 2.9 but 5% above its last 4 quarters average of 1.4
The company's equity fell by 8% YoY and by 6% QoQ
The stock's price to sales (P/S) is 100% more than its last 4 quarters average of 6.9 but 60% less than its 5-year quarterly average of 34.0
Zymeworks's revenue has plunged by 89% YoY and by 34% from the previous quarter

Efficiency

How efficient is Zymeworks business performance
Zymeworks's ROA has plunged by 161% YoY and by 8% from the previous quarter
Zymeworks's return on equity has shrunk by 156% YoY and by 8% QoQ
ZYME's ROIC has dropped by 135% year-on-year and by 5% since the previous quarter
ZYME's ROS has dropped by 62% since the previous quarter

Dividends

What is ZYME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZYME.

Financial health

How did Zymeworks financials performed over time
The total liabilities has decreased by 9% YoY
The company's current ratio rose by 9% YoY but it fell by 7% QoQ
The company's debt is 94% lower than its equity
The company's equity fell by 8% YoY and by 6% QoQ
The company's debt fell by 8% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.